Capricor/$CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ticker
$CAPR
Sector
Primary listing
Employees
160
Headquarters
Website
Capricor Metrics
BasicAdvanced
$357M
-
-$1.66
0.59
-
Price and volume
Market cap
$357M
Beta
0.59
52-week high
$21.01
52-week low
$5.68
Average daily volume
1.4M
Financial strength
Current ratio
4.371
Quick ratio
4.326
Long term debt to equity
0.185
Total debt to equity
0.995
Profitability
EBITDA (TTM)
-71.781
Gross margin (TTM)
-402.72%
Net profit margin (TTM)
-522.51%
Operating margin (TTM)
-548.15%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-53.40%
Return on equity (TTM)
-120.15%
Valuation
Price to revenue (TTM)
24.643
Price to book
3.4
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
-5.854
Free cash flow yield (TTM)
-17.08%
Free cash flow per share (TTM)
-1.334
Growth
Revenue change (TTM)
-50.68%
Earnings per share change (TTM)
77.36%
10-year revenue growth (CAGR)
8.76%
3-year earnings per share growth (CAGR)
16.58%
10-year earnings per share growth (CAGR)
-13.89%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Bulls say / Bears say
The FDA accepted Capricor’s BLA for deramiocel with Priority Review and set a PDUFA date of August 31, 2025, noting no review issues and positioning deramiocel to potentially be the first approved therapy for DMD cardiomyopathy (SEC filing).
H.C. Wainwright analyst Joseph Pantginis maintained that the opportunity to present to an FDA advisory committee could bolster deramiocel’s approval prospects, reflecting positive brokerage sentiment on the regulatory path (Reuters).
The FDA decided not to convene an external advisory panel for deramiocel, a move that may accelerate its review and streamline the path to potential approval (Reuters).
The FDA issued a Complete Response Letter on July 11, 2025 rejecting the deramiocel BLA for failing to demonstrate sufficient effectiveness and citing CMC deficiencies, causing shares to plunge about 50% (Reuters).
Capricor's stock dropped nearly 15% following the FDA’s announcement of an advisory committee review, underlining investor concerns over regulatory uncertainty (Reuters).
Capricor reported a net loss of $25.9 million for Q2 2025 and zero revenues, highlighting substantial cash burn and potential need for future financing (SEC 10-Q).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Capricor News
AllArticlesVideos
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Business Wire3 weeks ago
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Business Wire4 weeks ago
CAPR INVESTOR ALERT: Kirby McInerney LLP Notifies Capricor Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $357M as of October 08, 2025.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of October 08, 2025.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.